Clinical Trials Logo

Advanced Biliary Cancer clinical trials

View clinical trials related to Advanced Biliary Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06196658 Not yet recruiting - Pancreatic Cancer Clinical Trials

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Start date: January 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02 CAR T cell therapy in the treatment of patients with unresectable and/or metastatic pancreatic/bile duct cancer. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an intra-tumoral injection or intraperitoneal infusion of Ex02 CAR T cells, probably followed by an intravenous infusion of EX02 CAR T cells. Each participant will proceed through the following study procedures: - Screening - Enrollment/Leukapheresis - Conditioning chemotherapy - CAR T treatment - Post-treatment assessment - Long-term follow-up

NCT ID: NCT04809142 Recruiting - Clinical trials for Advanced Biliary Cancer

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Start date: February 4, 2021
Phase: Phase 3
Study type: Interventional

This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.

NCT ID: NCT00552149 Completed - Clinical trials for Advanced Biliary Cancer

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Start date: October 2007
Phase: Phase 2
Study type: Interventional

A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.